Lionel Larribère

Dr. Lionel Larribère

Skin Cancer Unit, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany;
+1

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LLLionel Larribère
Lionel Larribère
UMUwe M. Martens
Uwe M. Martens
The ability to detect minimal residual disease (MRD) after a curative-intent surgery or treatment is of paramount importance, because it offers the possibility to help guide the clinical decisions related adjuvant therapy. Thus, the earlier MRD is detected, the earlier potentially beneficial treatment can be proposed to patients who might need it. Liquid biopsies, and in particular the next-generation sequencing of circulating tumor DNA (ctDNA) in the blood, have been the focus of an increasing amount of research in the past years. The ctDNA detection at advanced cancer stages is practicable for several solid tumors, and complements molecular information on acquired therapy resistance. In the context of MRD, it is by definition more challenging to detect ctDNA, but it is technically achievable and provides information on treatment response and probability of relapse significantly earlier than standard imaging methods. The clinical benefit of implementing this new technique in the routine is being tested in interventional clinical trials at the moment. We propose here an update of the current use of ctDNA detection by NGS as a tool to assess the presence of MRD and improve adjuvant treatment of solid tumors. We also discuss the main limitations and medium-term perspectives of this process in the clinic.

22 April 2015 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
LLLionel Larribère
Lionel Larribère
HWHuizi Wu
Huizi Wu
DNDaniel Novak
Daniel Novak
MGMarta Galach
Marta Galach
MBMathias Bernhardt
Mathias Bernhardt
Jochen UtikalJochen Utikal
Jochen Utikal

27 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SASachindra
Sachindra
LLLionel Larribère
Lionel Larribère
DNDaniel Novak
Daniel Novak
HWHuizi Wu
Huizi Wu
LHLaura Hüser
Laura Hüser
Jochen UtikalJochen Utikal
Jochen Utikal
New role of ID3 in melanoma adaptive drug-resistance New role of ID3 in melanoma adaptive drug-resistance

10 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
LLLionel Larribère
Lionel Larribère
Jochen UtikalJochen Utikal
Jochen Utikal
Tumorigenesis is correlated with abnormal expression and activity of G protein-coupled receptors (GPCRs) and associated G proteins. Oncogenic mutations in both GPCRs and G proteins (GNAS, GNAQ or GNA11) encoding genes have been identified in a significant number of tumors. Interestingly, uveal melanoma driver mutations in GNAQ/GNA11 were identified for a decade, but their discovery did not lead to mutation-specific drug development, unlike it the case for BRAF mutations in cutaneous melanoma which saw enormous success. Moreover, new immunotherapies strategies such as immune checkpoint inhibitors have given underwhelming results. In this review, we summarize the current knowledge on cancer-associated alterations of GPCRs and G proteins and we focus on the case of uveal melanoma. Finally, we discuss the possibilities that this signaling might represent in regard to novel drug development for cancer prevention and treatment.

15 August 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
HWHuizi Wu
Huizi Wu
LLLionel Larribère
Lionel Larribère
QSQian Sun
Qian Sun
DNDaniel Novak
Daniel Novak
SSSachindra Sachindra
Sachindra Sachindra
Jochen UtikalJochen Utikal
Jochen Utikal

1 April 2008 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
CHC. Hilmi
C. Hilmi
LLLionel Larribère
Lionel Larribère
Marcel DeckertMarcel Deckert
Marcel Deckert
SRStephane Rocchi
Stephane Rocchi
SGSandy Giuliano
Sandy Giuliano
CBCorine Bertolotto
Corine Bertolotto